Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
MicroRNA Regulation of RNA Virus Replication and Pathogenesis

Derek W. Trobaugh¹ and William B. Klimstra¹,∗

microRNAs (miRNAs) are non-coding RNAs that regulate many processes within a cell by manipulating protein levels through direct binding to mRNA and influencing translation efficiency, or mRNA abundance. Recent evidence demonstrates that miRNAs can also affect RNA virus replication and pathogenesis through direct binding to the RNA virus genome or through virus-mediated changes in the host transcriptome. Here, we review the current knowledge on the interaction between RNA viruses and cellular miRNAs. We also discuss how cell and tissue-specific expression of miRNAs can directly affect viral pathogenesis. Understanding the role of cellular miRNAs during viral infection may lead to the identification of novel mechanisms to block RNA virus replication or cell-specific regulation of viral vector targeting.

Introduction

RNAi evolved in plants and invertebrates as an antiviral mechanism, combating viral infections through degradation of viral RNA into siRNAs that bind viral nucleic acids and thus inhibit viral replication [1]. In vertebrates RNAi functions as an antiviral mechanism in non-differentiated embryonic stem cells only [2,3]. In differentiated vertebrate somatic cells, type I interferon (IFN) (see Glossary) and the antiviral effectors IFN-stimulated genes (ISGs) have evolved to mediate the majority of cellular antiviral responses [4]. The vertebrate RNAi system regulates the function of cellular mRNA through tissue- and cell-specific expression of host-cell-encoded miRNAs that bind mRNAs and alter their translation or abundance [5]. To date >5500 miRNAs have been predicted throughout the human genome [6] with many limited to specific tissues [5]. Invertebrates also use miRNAs to regulate mRNA translation and control protein abundance (reviewed in [7]). Recent evidence indicates that host miRNAs also bind to RNA virus genomes, regulating their translation and replication and altering viral pathogenesis. RNA virus infection can mediate changes in the expression of cellular miRNAs leading to downstream changes in the host transcriptome that can be advantageous to the virus. However, changes in miRNA expression can also lead to increases in antiviral effector activities resulting in decreased viral replication. This review focuses on recent advances in our understanding of RNA viruses and how they have evolved to use host miRNAs to evade antiviral immune responses, leading to enhanced viral replication and pathogenesis.

Factors Influencing miRNA–RNA Virus Interactions

miRNAs are small noncoding RNAs located primarily within the introns of both coding and noncoding host RNAs (Box 1). miRNAs bind to miRNA-binding sites within miRNAs and viral genomes to mediate miRNA function [8,9]. Naturally occurring miRNA-binding sites within viral genomes are generally located in the 5′ [10] and 3′ non-translated regions (NTRs) [11] but have recently been found in the coding regions of viral proteins [12,13]. Increasing the number of miRNA-binding sites in a viral 3′ NTR with perfect complementarity to the target miRNA has led...
Box 1. Biochemistry of miRNA–RNA Virus Interactions

miRNA genes are transcribed by RNA polymerase II into primary miRNA (pri-miRNA) transcripts containing a stem-loop structure encompassing the miRNA of interest [82]. Within the cell nucleus, pri-miRNA is digested enzymatically by the Drosha protein into pre-miRNA containing a hairpin structure, which is exported from the nucleus into the cytoplasm (Figure 1) [83]. Subsequently, the Dicer protein cleaves the terminal loop structure of the hairpin leaving a small, 21–23-nucleotide miRNA duplex. The argonaute protein then associates with one strand of the miRNA duplex to form the RISC, mediating translational repression or mRNA destabilization [84,85]. Each strand in the miRNA duplex can function as an miRNA and be loaded into the RISC; however, the strand that is more thermodynamically unstable at the 5’ end is incorporated preferentially [86]. For a more detailed review of miRNA processing, see [85].

A seed sequence located at nucleotide positions 2–8 of the 5’ end of the miRNA binds complementary sequences within the 3’ NTR of either a host miRNA or the genome of an invading RNA virus [87]. A single miRNA can possess binding specificity for many different target mRNAs based on the cell type and the pattern of miRNA expression [88]. A perfect match between the miRNA and the entire miRNA target sequences leads to RNA cleavage, albeit rarely in mammals [87]. More commonly, an exact seed sequence match, – a canonical miRNA-binding site without complete complementarity in the remainder of the target mRNA – results in translation inhibition and, eventually, RNA destabilization and degradation [84,85]. Recently, noncanonical binding sites have also been described that have imperfect seed sequence complementarity. As an example, noncanonical miRNA-binding sites are thought to comprise up to 40% of the total miR-155 miRNA-binding sites in host mRNAs [89]. However, although noncanonical binding sites may mediate miRNA binding to the mRNA, these sites may not fully suppress miRNA translation [90]. If miRNAs can functionally inhibit RNA viruses through noncanonical interactions, the number of potential miRNA–RNA virus interactions would dramatically increase. Mutational analysis of known miRNA-binding sites into noncanonical target sequences will be required to determine whether such noncanonical interactions can mediate productive miRNA–RNA virus interactions.

to increased translational repression in vitro and greater attenuation in mice [14]. In similar studies, cooperativity between two or more miRNA-binding sites enhanced repression of miRNA translation via an unknown mechanism when sites were separated by 13–35 nucleotides [15]. Therefore, the location and number of miRNA-binding sites within a viral genome can influence miRNA function. Naturally occurring viral miRNA-binding sites within viral RNAs may not be uniformly distributed or have perfect complementarity to the miRNA. Further experimental validation will be required to determine whether cooperativity between viral miRNA-binding sites leads to enhanced transcriptional repression. Furthermore, empirical studies are needed for all miRNA–viral interactions identified in silico – as computational methods might not fully recapitulate the cellular environment – to identify interactions that are not functional due to higher-order target RNA structures or other nucleic acid interactions.

Transcriptional, epigenetic, and environmental conditions drive miRNA gene transcription leading to temporal and cell-specific miRNA expression [16]. Common laboratory practices can also alter the miRNA environment within a cell. For example, culturing cells can reduce miRNA levels compared with primary tissues [17] and cells at a higher confluency can exhibit increased miRNA levels compared with less confluent cells due to increased cell–cell contact [18]. Compared with cells isolated from primary tissues, it is commonly known that cancer cell lines have different expression patterns of miRNAs that can contribute to carcinogenesis [19]. C6/36 cells derived from Aedes aegypti mosquitoes do not efficiently cleave viral RNA into siRNAs for use in the antiviral RNAi pathway but can still process miRNAs [20]. By contrast, Aag2 cells derived from Aedes albopictus mosquitoes have a functional double-stranded RNA processing pathway and can generate both siRNAs and miRNAs [21]. Furthermore, studies that globally inhibit the RNAi pathway in single cell types [22] are likely to fail in detecting cell/tissue-specific miRNA–viral interactions and can underestimate the impact of cell-specific miRNA–viral interactions occurring in infected hosts. Finally, in vitro models may not fully characterize how miRNA–viral interactions alter global cellular miRNA levels [23], which could possibly lead to important changes in paracrine or autocrine signaling in intact hosts [11]. Knowledge of the pathobiological features of a viral infection within a specific host (e.g., unexplained restriction in particular tissues) and using disease-relevant cell lines that express an miRNA of interest might also lead to the identification of cell-specific miRNAs that contribute to viral pathogenesis.
While miRNA–RNA viral genome interactions are governed by many of the same mechanisms governing miRNA–mRNA interactions, investigation of their role in viral pathogenesis should take into account cell specificity, the role of noncanonical miRNA target sites, the potential for mild alteration of viral activities at the cellular level leading to large effects in the host, and the potential for miRNA inhibition to alter cell–cell signaling in the complex environment of an infected animal. These ideas are explored in greater detail below.

miRNA Interactions with the RNA Viral Genome

Evidence is accumulating that host miRNAs can bind to a broad range of RNA viruses, directly regulating their pathogenesis (Table 1). A positive-strand RNA virus genome mimics cellular mRNAs allowing direct binding of the miRNA to the viral RNA, and potentially the regulation is analogous to that of host mRNAs. Two outcomes of these interactions have thus far been identified where viral replication is directly altered: (i) inhibition of translation of the viral genome preventing viral replication [11]; and (ii) stabilization of the virus RNA thereby enhancing replication (Figure 1, Key Figure) [10,24]. Both of these mechanisms reveal a novel method for regulating RNA virus replication within specific cells and/or tissues. In addition to expression of the virus receptor on the cell surface, miRNA-mediated virus repression may be another mechanism for determining cell permissiveness to infection. Another commonality of these two target mRNAs can direct these mRNAs to P bodies for storage or decay through decapping mechanisms or 5′–3′ exonuclease activity mediating translational repression.

Primate foamy retrovirus type 1 (PFV-1): establishes lifelong persistent infection in humans and primates without causing signs of disease, which is unique to PFV.

Prodrome: the initial set of clinical symptoms that a viral infection elicits in an infected animal may progress to different or more severe manifestations of infection.

Retinoic acid-inducible gene I (RIG-I): RNA helicase and pattern-recognition receptor that recognizes single-stranded RNA containing a 5′ triphosphate molecule leading to a signaling cascade initiating innate immune responses.

RNA-induced silencing complex (RISC): functional set of cellular proteins including argonaute proteins, which associate with the miRNA seed sequence to mediate binding of the RISC to complementary sequences in target RNAs. The binding of the RISC to target RNAs leads to translational repression or destabilization of the target RNA.

Seed sequence: nucleotides 2–8 at the 5′ end of an miRNA that determine the target specificity of the miRNA by binding to complementary sequences in the target RNA. A single miRNA can bind to many different target RNAs based on the seed sequence.

Translational repression: a functional outcome of miRNA binding to target RNA that results in reduced translation of the RNA leading to lower protein levels within the cell.

Type I interferon (IFN): a primary antiviral molecule that functions in both an autocrine manner—by upregulating ISGs leading to increased IFN production within the same cell—and a paracrine manner by priming naive cells via the upregulation of antiviral ISGs.

Viral quasispecies: viruses that arise due to mutation of the virus genome; they compete for a fitness advantage within the host.

| Virus | miRNA | Phenotype | Refs |
|-------|-------|-----------|------|
| EEEV  | miR-142-3p | ↓ Viral translation and replication, myeloid cell replication, serum IFN-α/β, lymph node replication | [11] |
|       | miR-181 | ↓ Viral translation | [10,24,48] |
|       | miR-391 | ↓ Viral replication | [13] |
|       | miR-485 | ↑ Viral translation and replication | [32] |
|       | miR-654 | ↓ PB1 RNA levels | [12,33,34] |
|       | miR-3145 | ↓ Matrix protein | [35] |
|       | miR-21 | ↓ VP1 protein levels | [38] |
|       | miR-181, miR-206 | ↓ Viral translation and replication | [39] |
|       | miR-23, miR-378, miR505 | ↓ Viral translation and replication | [40] |
|       | miR-122 | ↓ RNA stability, viral replication, cell proteins repressed by miR-122 | [10,24,48] |
|       | miR-17 | ↓ RNA stability and viral translation, cell proteins repressed by miR-17 | [23] |

↑, Increase; ↓ decrease.
Figure 1. miRNAs are transcribed in the nucleus by RNA polymerase II (Pol II) into a primary miRNA (pri-miRNA) that is cleaved by Drosha resulting in a pre-miRNA. The pre-miRNA is exported from the nucleus into the cytoplasm and is enzymatically cleaved by Dicer into the miRNA duplex. One strand of the miRNA duplex is recognized by the argonaute proteins to form the RNA-induced silencing complex (RISC). Direct interaction: After infection, the RNA virus genome is released into the cytoplasm where the miRNA-loaded RISC binds via the miRNA seed sequence to complementary nucleotides in the viral 5’ non-translated region (NTR), 3’ NTR, or coding regions. miRNA binding to the 5’ NTR leads to RNA stability and increased viral replication. miRNA binding to the 3’ NTR can lead to inhibition of viral translation or increased RNA stability and viral translation. Indirect interaction: Viral RNA is recognized by pattern-recognition receptors, Toll-like receptor (TLR)3, TLR7, and retinoic acid-inducible gene I (RIG-I) or melanoma differentiation-associated protein 5 (MDAS), leading to induction of the interferon (IFN) signaling cascade and upregulation of IFN-α, IFN-β, and other IFN-stimulated genes (ISGs) that inhibit viral replication. Viral infection and IFN and ISG induction can also lead to changes in miRNA expression within a cell. These upregulate or downregulate proteins involved in the IFN signaling cascade or ISG expression and function, as well as cellular proteins required for viral replication. Collectively, these virus-mediated changes in miRNA levels result in either a proviral or an antiviral environment.
mechanisms is that both lead to a fitness advantage for the virus at the level of the infected host, either directly by increasing replication – as with hepatitis C virus (HCV) [10,24] – or indirectly by suppressing innate immune responses and leading to increased overall host-level replication, as in the case of eastern equine encephalitis virus (EEEV) [11]. Considering the ability of RNA viruses to rapidly alter their genomes in the face of selective pressure [25], it may be that productive miRNA–RNA viral interactions are maintained only when a significant replicative advantage is conferred on the virus. Below, the outcomes of direct binding of miRNA to RNA viral genomes are discussed in detail.

Translational Inhibition of the RNA Viral Genome by Direct miRNA Binding

**Alphaviruses.** EEEV, an alphavirus, causes the most acutely virulent mosquito-borne viral disease in the USA, with a >30% mortality rate in humans and long-term neurological sequelae in surviving individuals [26]. In humans EEEV infection is characterized by a limited disease prodrome before the manifestation of encephalitis due to the inability of EEEV to replicate in hematopoietic cells and to elicit a strong innate immune response [11,27]. EEEV is a positive-sense RNA virus that encodes three canonical and one noncanonical miRNA-binding sites in the 3’ NTR that are specific for the hematopoietic cell-specific miRNA miR-142-3p [11]. miR-142-3p expression has been shown to prevent translation of the incoming EEEV genome and prevent virus replication in both human and murine macrophages as well as dendritic cells [11]. This inhibition of myeloid cell replication prevented IFN-α/β induction in vivo, directly contributing to the extreme virulence of EEEV that is seen in mice, and presumably in humans [11]. Mutation of the miR-142-3p-binding sites in the EEEV genome has been shown to allow virus translation and replication in both human and murine myeloid cells, which was shown to lead to systemic IFN-α/β production and virus attenuation in mice. Presumably, strong selective pressure has maintained these miR-142-3p-binding sites, since 17 of 23 North American EEEV strains isolated from nature have the same sequence and location of miR-142-3p binding sites within the 3’ NTR [11].

**Retroviruses.** Retroviruses are single-stranded, positive-sense RNA viruses with two different points in the virus life cycle where miRNAs can bind to virus RNA: the genomic RNA and the RNA transcribed from integrated DNA. For example, *primate foamy retrovirus type 1 (PFV-1)* encodes a binding site for miR-32 in the 3’ NTR of multiple protein transcripts that can inhibit PFV-1 replication. To evade miR-32 repression, PFV-1 encodes a transactivator protein, Tas, that nonspecifically suppresses the miRNA processing pathway and potentially inhibits the production of miRNAs that might limit virus replication, including miR-32 in infected mammalian cells [28].

**Human T cell leukemia virus, type I (HTLV-1)** translation is inhibited in resting human T cells by miR-28-3p. A single nucleotide variant in the miR-28-3p target sequence of the Japanese ATK-1 strain has been shown to confer miR-28-3p translational repression resistance, increasing virus replication as well as transmission between individuals, occurrences not normally seen with other HTLV-1 strains [29]. miRNA can also contribute to retroviral latency within T cells by preventing translation of the virus RNA and suppressing virus replication. For example, during HIV-1 infection of CD4+ T cells in vitro, expression of miR-28-5p, miR-150, miR-223, and miR-232 has been found to mediate translational repression of HIV-1 RNA [30]. Another miRNA, miR-29a, functions through a different mechanism to restrict viral replication during HIV-1 infection by binding to the 3’ NTR leading to its increased association with the RNA-induced silencing complex (RISC) and P bodies and thus preventing virus translation [31].

**Picornaviruses.** Similar inhibition of virus translation and replication occurs following upregulation of miR-296-5p by the positive-sense picornavirus family member *enterovirus 71 (EV71)*. miR-296-5p negatively regulates virus replication in a human neuronal cell line due to the presence of two miR-295-5p-binding sites in the coding regions of virus proteins VP1 and VP3 [13]. Natural variants of EV71 bear mutations in the miR-296-5p-binding sites rendering this virus insensitive.
to miR-296-5p restriction [13]. EV71 also contains a binding site for miR-23b; however, miR-23b is naturally downregulated during EV71 infection of monkey epithelial cells, preventing miR-23b binding to the virus genome and inhibiting virus replication [32].

Orthomyxoviruses. miRNAs can also bind to negative-strand RNA viruses after transcription of the negative-strand RNA genome into the positive-sense RNA intermediate needed for virus replication. For instance, miR-323, miR-491, miR-485, miR-654, and miR-3145 have been shown to bind to the coding region of the influenza PB1 gene segment leading to RNA degradation in infected human and canine epithelial cell lines in vitro [12,33,34]. Similar degradation of virus RNA was found when the miRNA let-7c bound to the 3′ NTR of the influenza matrix protein in human alveolar epithelial A549 cells [35]. Other potential miRNA-binding sites in the influenza RNA genome have been computationally predicted; however, they have yet to be experimentally validated [36,37]. Although an miRNA may restrict influenza virus replication in cell culture, it may not be constitutively expressed in infected cells in vivo and therefore may not necessarily affect viral pathogenesis in vivo [33].

Other Viruses. Finally, interactions between miRNAs and RNA viruses also occur with nonhuman viruses. In chickens infectious bursal disease virus replication is inhibited by miR-21 due to miR-21-binding sites in the coding region of the VP1 protein [38]. In pigs naturally minimally permissive cells can express multiple miRNAs that inhibit replication of porcine reproductive and respiratory syndrome virus (PRRSV) [39,40]. Treatment with a miR-181 mimic limits PRRSV replication in vivo leading to extended infected-pig survival times, thus demonstrating the therapeutic potential of this miRNA during an RNA virus infection [39]. While these studies suggest widespread negative regulation of RNA virus replication by host cell miRNAs, the capacity for RNA viruses to mutate rapidly to eliminate miRNA binding [9,41,42] indicates that direct antiviral activities of miRNAs may be limited to particular cells or to a subset of viral quasispecies present at any given time within the host. Therefore, any antiviral effects at the cellular level should be considered in the context of the overall effect of tissue-specific viral inhibition on viral quasispecies fitness in the intact host and on transmission between hosts.

miRNA-Mediated Stabilization of RNA Virus Genomes: A Focus on Flaviviruses

A noncanonical interaction between miRNAs and RNA viruses has been identified that leads to increased stability of the viral RNA. The most studied interaction of this type was first identified in 2005 and occurs between liver-specific miR-122 and HCV. Rather than binding to the 3′ NTR, miR-122 bound to the 5′ NTR of HCV [10] preventing 5′ host exoribonuclease activity and RNA degradation in the infected human hepatocarcinoma-derived cell line Huh-7 [24]. Moreover, removal of miR-122 from Huh-7 cells could reduce HCV replication [10]. Thus, miR-122 is currently an active target for antiviral therapeutics in the treatment of chronic HCV infection [10,43]. Recently, miRNAs were also found to increase RNA stability through interactions with the 3′ NTR; miR-17 and let-7c both bound to the 3′ NTR of the bovine viral diarrhea virus (BVDV) genome increasing virus translation and RNA stability rather than causing translational repression [23]. Interestingly, let-7 sites are present within several RNA viruses, including alphaviruses [23]. The ability of two diverse members of the Flaviviridae family, HCV and BVDV, to utilize host miRNAs to help stabilize virus RNA through two different sites within the virus genome suggests that this interaction might have evolved independently. It will be interesting to determine whether other virus families use miRNAs in a similar manner to help stabilize viral RNA.

Modulation of Host miRNA Levels during Viral Infections

Recognition of viral infection by pattern-recognition receptors initiates the innate immune response signaling cascade leading to transcription factor activation and changes in the cell transcriptome, including changes in miRNA expression (Figure 1) [44]. It has been proposed that a critical role for miRNAs during a viral infection is in the modulation of cytokine responses, either
by augmenting productive responses or by suppressing potentially damaging responses [45]. Specific miRNA expression patterns have been associated with pathogenic versus attenuated influenza virus [46] and hantavirus (Hantaan) [47] infections. Viruses may also alter global miRNA activity by binding and sequestering free miRNA. For example, miR-122 binding to HCV has been shown to sequester and reduce free miR-122 inside Huh-7 cells leading to changes in expression of the cellular proteins that are normally repressed by miR-122 [48]. Although both miR-17 and let-7c can bind the BVDV genome, only miR-17 sequestration has been reported to lead to changes in the host transcriptome, demonstrating that not all miRNA–RNA interactions lead to similar results [23]. Such changes in the host transcriptome due to sequestration may positively or negatively affect viral replication and pathogenesis and may vary depending on the cell and tissue expression of each miRNA. Finally, RNA viruses can encode proteins that modulate the miRNA or RNAi pathway, especially in invertebrates (Box 2). Moreover, as discussed below, RNA virus infection can lead to many changes in miRNA expression (Table 2) influencing viral replication as well as host immune responses.

miRNA-Mediated Changes in Protein Expression That Alter Host Responses to Infection

In addition to tissue-specific changes in miRNA expression during viral infections (Box 3), other important changes in miRNA-mediated protein expression can occur. For instance, IFN-α/β is a key cytokine induced by viral infection that leads to the downstream upregulation of antiviral ISGs. Viruses have evolved multiple mechanisms to evade the IFN system to establish a productive infection. Typically, during an infection viral proteins inhibit either pattern-recognition receptor recognition or downstream signaling cascades to prevent ISG induction [49]. However, a role for virus-mediated regulation of the IFN signaling cascade through changes in host miRNA levels has recently been proposed. For example, EV71 [50], dengue virus (DENV) [51], and Japanese encephalitis virus (JEV) [52] induction of miR-146a in infected cells has been shown to negatively regulate the IFN signaling protein tumor necrosis factor receptor-associated protein 6 (TRAF6), thus preventing the induction of IFN-α/β. In addition, downregulation of miR-432 by JEV infection has been reported to increase expression of the negative regulator of cytokine signaling suppressor of cytokine signaling 5 (SOCS5) in infected human microglial cells, thereby dampening the antiviral response [53]. Induction of miR-29c, miR-451, and miR-485 in influenza-infected cells has also been found to limit cytokine and chemokine responses through inhibition of various antiviral proteins (Table 2) and to prevent overactive IFN and inflammatory responses [34,54,55]. HCV infection can upregulate miR-758 [56], miR-130a [57], and miR-373 [58], inhibiting various components of IFN signaling to decrease IFN-α/β production (Table 2). Another example is avian leukemia virus subgroup J infection, in which chicken spleen was shown to lead to miR-23b expression and downregulation of both IFN regulatory factor 1 (IRF1)
## Table 2. Changes in Cellular miRNA Expression after RNA Virus Infection

| Virus           | miRNA | Protein target                  | Phenotype                                      | Refs  |
|-----------------|-------|---------------------------------|------------------------------------------------|-------|
| EV7             | ↑ mR-146a | ↑ TRAF6, IRAK1, SOS1            | ↓ IFN-α/β, Apoptosis                           | [50]  |
|                 | ↓ mR-141 | ↓ eIF4E                        | Host translation                               | [70]  |
|                 | ↓ mR-370 | ↓ GADD45β                      | Apoptosis                                      | [107] |
|                 | ↑ mR-526a | ↑ CYLD                         | ↓ IFN-α/β, Viral replication                    | [66]  |
| DENV            | ↑ mR-146a | ↑ TRAF6                        | ↓ IFN-α/β                                      | [51]  |
|                 | ↑ mR-30e* | ↑ IκBα, ↓ IFN-β, OAS1, MxA, IFITM1 | Viral replication                              | [61]  |
| JEV             | ↑ mR-146a | ↑ TRAF6                        | ↓ IFN-α/β                                      | [52]  |
|                 | ↓ mR-432 | ↑ SOCS5                        | ↓ IFN-α/β                                      | [53]  |
|                 | ↑ mR-155 | ↑ SHIP1                        | ↓ IFN-β, proinflammatory cytokines             | [99]  |
|                 | ↑ mR-15b | ↑ RNF125                       | ↑ RIG-I                                        | [101] |
|                 | ↑ mR-29b | ↑ TNFAIP3                      | Proinflammatory cytokines                      | [100] |
| Influenza virus | ↑ mR-24 | ↑ Furin                         | Hemagglutinin cleavage                         | [68]  |
|                 | ↓ mR-548an | ↑ NS1-binding protein            | Apoptosis                                      | [69]  |
|                 | ↓ mR-4276 | ↑ COX6C                        | Caspase-9, Viral replication                    | [109] |
|                 | ↑ mR-485 | ↑ RIG-I                         | ↓ IFN-α/β                                      | [34]  |
|                 | ↑ mR-29c | ↑ TNFAIP3                      | Proinflammatory cytokines                      | [54]  |
|                 | ↑ mR-451 | ↑ YWHAZ/14-3-3ζ                | IL-6, TNF, CCL5, CCL3                          | [55]  |
| HCV             | ↑ mR-758 | ↑ TLR3/7                       | ↓ IFN-α/β                                      | [56]  |
|                 | ↑ mR-373 | ↑ JAK1, IRF9                    | ↓ IFN-α/β                                      | [58]  |
|                 | ↑ mR-130a | ↑ ISG15, USP18, MxA, ↓ mR-122, IFITM1 | Viral replication                              | [60]  |
|                 | ↑ mR-146a-5p | N.D.                           | Viral assembly and egress                      | [71]  |
| Hendra virus    | ↑ mR-146a | ↑ RNF11                        | ↓ NF-κB, Viral replication                     | [110] |
| WNV             | ↑ mR-532-5p | ↑ SEDT1, TAB3                  | Viral replication                               | [62]  |
|                 | ↑ mR-6124 | ↑ CTCF, ECOP                   | Apoptosis                                      | [108] |
| Coxsackie B3 virus | ↑ mR-19b | ↑ GJA1                         | ↓ Pathogenesis, myocarditis                    | [105] |
|                 | ↑ mR-1 | ↑ GJA1, KCNJ2                  | Pathogenesis, myocarditis                      | [105,106] |
| RSV             | ↑ mR-221 | ↑ NGF, TrKA                    | Apoptosis, Viral replication                    | [72]  |
|                 | ↑ let-7f | ↑ SOCS3, ELF4, DYRK2, CCND1    | Viral replication                               | [67]  |
|                 | ↑ let-7b, let-7l, mIR-30b | N.D.                           | ↓ IFN-β, Viral replication                      | [65]  |
| Coronavirus OC43 | ↑ mR-9  | ↑ NFKB1                        | ↓ NF-κB                                        | [64]  |
levels and innate immune induction [59]. It is likely that future work will identify more miRNAs that are involved in downregulating the innate immune response during RNA virus infections.

Viral infection may also increase the levels of miRNAs leading to the upregulation of antiviral molecules that are detrimental to viral replication. For example, while miR-130a can downregulate IFN-induced transmembrane protein 1 (IFITM1) protein levels after HCV infection to increase virus replication [57], miR-130a induction can also lead to antiviral ISG expression, increased IFN production, and reduced virus replication in Huh-7.5.1 hepatocarcinoma cells [60]. These results demonstrate that the same miRNA can have pleiotropic effects during virus infection, which may be due to two different mechanisms: direct targeting of a cellular protein (IFITM1) [57] or targeting of an unknown master regulator that controls the expression of many ISGs [60]. Interestingly, upregulation of miR-130a following HCV infection can also downregulate the expression of miR-122, providing a second mechanism to limit HCV replication [60]. Following DENV infection of a human monocyte cell line, miR-30e* induction has been shown to suppress virus replication by downregulating nuclear factor kappa B (NF-κB) inhibitor alpha (NFKBIA or IκBα) leading to continual NF-κB activation and upregulation of ISGs and IFN-α/β production [61]. Finally, rather than modulating ISG levels, miR-532-5p upregulation during West Nile virus (WNV) infection has been shown to lead to downregulation of SEC14 and of spectrin domain-containing 1 (SESTD1) and TGF-beta-activated kinase 1/MAP3K7-binding protein 3 (TAB3), two proteins required for virus replication in infected human embryonic kidney (HEK) 293 cells [62].

With some viruses, virus-encoded proteins can inhibit the upregulation of miRNAs that are triggered after viral infection to suppress the innate immune response. For example, the borna virus...
**disease virus** phosphoprotein was shown to inhibit the expression of a known regulator of innate immune responses, miR-155, limiting the induction of IFN-α/β during infection in human oligodenroglioma cells [63]. Also, the **coronavirus** OC43 nucleocapsid protein has been found to bind the NF-κB negative regulator miR-9 in HEK293T cells, allowing continual NF-κB translation; however, the role of this activity during coronavirus infection remains unclear [64]. The respiratory syncytial virus (RSV) NS1 and NS2 proteins can antagonize let-7i and miR-30b induction through the inhibition of innate immune signaling proteins in human bronchial epithelial cells [65]. EV71 3C protein can block the upregulation of miR-526a by degrading IRF7 and preventing enhancement of **retinoic acid-inducible gene I** (RIG-I) signaling [66]. Finally, virus protein expression can also lead to the upregulation of miRNAs, as in the case of the RSV G protein, which can increase let-7i expression, negatively regulating IFN production and delaying virus clearance in human alveolar epithelial A549 cells [67]. Potentially, viral protein-mediated changes in miRNA expression may occur through an indirect mechanism governed by viral inhibition of the innate immune response rather than a direct interaction between the viral protein and the transcription factors that regulate miRNA expression, but further experiments would be required to elucidate this point.

**miRNA-Mediated Changes in Protein Expression That Promote Viral Replication**

As described above, miRNA sequestration and/or alteration of expression levels by RNA viruses can lead to cellular transcriptome changes that promote favorable conditions for viral replication. For example, influenza virus infection has been shown to downregulate miR-24 in A549 cells leading to increased furin protease levels and, thus, increased cleavage of the influenza hemagglutinin protein, leading to increased numbers of infectious influenza particles [68]. Also in A549 cells, influenza virus downregulation of miR-548an was shown to lead to increased NS1-binding protein levels and increased RNA stability by decreasing cellular apoptosis [69]. In another study EV71 infection increased miR-141 levels in human rhabdomyosarcoma cells, leading to the downregulation of eukaryotic translation initiation factor 4E protein and thus contributing to the switch from cap-dependent translation of cellular mRNAs to cap-independent translation of virus RNAs [70]. Furthermore, miR-146a-5p upregulation after HCV infection of human hepatocytes and in liver tissues from HCV-infected patients has been shown to promote the assembly of virus particles and egress from an infected cell, increasing HCV infection, through an unknown mechanism [71]. In another example RSV infection of human bronchial epithelial cells resulted in the downregulation of miR-221 levels, preventing infected cell apoptosis and leading to increased virus replication [72]. Finally, transfection of miRNAs into cells before virus infection has led to the identification of novel proteins involved in virus replication, such as heterogeneous nuclear ribonucleoprotein C (C1/C2) (hnRNP C) and leukemia inhibitor factor (LIF) in poliovirus [73] and influenza infections, respectively [74]. The use of miRNA expression screens to identify novel cellular proteins involved in virus replication will be more common in the future. However, confirmation of the role of these miRNAs in vivo will be needed to determine their specific functional contribution to viral replication and pathogenesis.

**Maintenance of miRNA-Binding Sites in the RNA Virus Genome**

RNA viruses can mutate rapidly due to the lack of proofreading activity in the RNA polymerase [75]. Therefore, positive selection, or at least the absence of negative selection, is likely to be required to maintain the miRNA-binding sites within the virus genome. For example, EEEV replication in a non-miR-142-3p-expressing mammalian cell line resulted in a 238-nucleotide deletion in the 3’ NTR encompassing all of the miR-142-3p-binding sites [41]. Similarly, artificially inserted miRNA-binding sites in the 3’ NTR of DENV [42] and tick-borne encephalitis virus (TBEV) [14] were deleted in vivo during infection in mice. These results demonstrate that miRNA-binding sites in the 3’ NTR without a positive influence on virus replication can be rapidly deleted in vivo. Therefore, it is unclear how sites that negatively impact replication might be retained in virus populations. With EEEV, replication in the mosquito vector appears to provide positive selection
Box 4. The Clinician’s Corner

miRNAs play a role in many different processes within a cell by regulating the production of cellular proteins. miRNA regulation of the innate immune response modulates the production of antiviral molecules by enhancing their response during the initiation of innate immunity, but also by downregulating this response to prevent aberrant physiological responses and/or immunopathology in a host.

Cell-specific miRNA expression directly contributes to the pathogenesis of medically important viruses either by promoting avoidance of the innate immune response (e.g., EEEV) or by stabilizing the viral genome and enhancing viral replication (e.g., HCV).

Other miRNAs can be regulated via viral infection to establish a pro- or antiviral environment. miRNA expression patterns can be used to identify a viral infection and help to determine whether a viral strain is pathogenic or attenuated.

In the future miRNAs might be used as antiviral therapeutics to prevent certain viral infections. Furthermore, the incorporation of tissue-specific miRNAs into viral vaccine and gene therapy vectors might enhance the specific targeting of viral proteins and/or, hopefully, limit adverse reactions due to infection.

for retention of miR-142-3p-binding sites, as deletion of the sites decreased virus replication in mosquito cell cultures and greatly suppressed acquisition by mosquito vectors [11]. By contrast, site removal has no impact on replication in mammalian cells that do not express the miRNA. Mosquitoes do not express miR-142-3p [76], suggesting that another, unknown mechanism underlies the requirement for these sites for efficient replication.

The presence of miRNA-binding sites within many different RNA viruses may suggest a positive selective pressure for retention of these sites within the genome occurring at the cellular or organismal level or during virus transmission between hosts, particularly in instances where replication is inhibited at the single-cell level. Consequently, miRNA repression of viral replication may exert powerful effects on the composition of RNA virus quasispecies during different phases of virus residency within a host. One potential selective pressure to maintain miRNA-binding sites may result from tempering of viral replication in certain cells or tissues that enables efficient virus dissemination without severe detrimental effects to the host. However, it is clear that more research is needed to fully understand how the replication-inhibiting miR-142-3p-binding sites in EEEV, and specific sites in other viruses, can be maintained throughout the virus replication/transmission cycle.

Concluding Remarks

miRNAs regulate many processes within cells, including RNA virus infections. Direct binding of miRNAs to viral genomes that leads to an antiviral effect may be rare due to the high mutation rate of RNA viruses, unless there is a strong selective pressure to maintain the miRNA-binding sites within the viral genome. It may be more common for RNA viruses to manipulate the levels of particular miRNAs within the cell to establish a proviral environment that enhances viral replication and dissemination within and between hosts. In addition, changes in miRNA levels after viral infection are clearly an important component of the host response to infection, sculpting both the initiation and the resolution phases of the antiviral response.

Over the past few years, there has been a large expansion in the number of studies identifying miRNAs as modulating factors during RNA virus infections. Future work (see Outstanding Questions and Box 4) will help to define the role of miRNAs during these processes. However, knowledge regarding the role of miRNAs has already been applied to the development of antiviral therapeutics [43] and gene therapy vectors (reviewed in [77]). An miRNA therapeutic for Ebola virus was used during the recent outbreak in Africa; however, testing was ultimately suspended as the drug did not demonstrate a significant role in patient recovery [78]. Also, insertion of tissue-specific miRNA-binding sites has been used as an effective mechanism to prevent virus
replication in particular tissues as an attenuation mechanism for vaccines, helping to limit adverse events [79]. Furthermore, recent evidence suggests the presence of virus-derived small RNAs during infection of both mammalian and arthropod cells [80,81]. While controversial, their presence and function during animal infections will need to be further examined. Viral interactions with the miRNA system can affect cellular miRNA and transcriptome levels as well as viral replication within a cell expressing a specific miRNA; these may indirectly modulate cytokine expression and tissue responses throughout an infected host. Consequently, future approaches tackling these questions are likely to emerge from this exciting area of investigation.

Acknowledgments

This work was supported by funds from the National Institutes of Health (R01 AI065436, R21 AI111115, and R21 AI117331) and the Defense Threat Reduction Agency (HDTRA1-15-1-0047) to W.B.K.

References

1. Ding, S.-W. and Volnet, O. (2007) Antiviral immunity directed by small RNAs. Cell 130, 413–426
2. Mallard, P.V. et al. (2013) Antiviral RNA interference in mammalian cells. Science 342, 235–238
3. Li, Y. et al. (2013) RNA interference functions as an antiviral immunity mechanism in mammals. Science 342, 231–234
4. Schneider, W.M. et al. (2014) Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32, 513–545
5. Ludwig, N. et al. (2016) Distribution of miRNA expression across human tissues. Nucleic Acids Res. 44, 3865–3877
6. Londin, E. et al. (2015) Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc. Natl. Acad. Sci. U.S.A. 112, E1106–E1115
7. Lim, L.P. et al. (2003) The microRNAs of Caenorhabditis elegans. Genetics Dev. 17, 991–1003
8. Grimson, A. et al. (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91–105
9. Teterina, N.L. et al. (2014) Silencing of neurotrophic flavivirus replication in the central nervous system by combining multiple microRNA target insertions in two distinct viral genome regions. Viruses 6, 247–258
10. Jojling, C.L. et al. (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309, 1577–1581
11. Tatrobaugh, D.W. et al. (2014) RNA viruses can hijack vertebrate microRNAs to suppress innate immunity. Nature 506, 245–248
12. Song, L. et al. (2013) Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells. J. Virol. 84, 8849–8860
13. Zheng, Z. et al. (2013) Human microRNA has-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome. J. Virol. 87, 5645–5666
14. Heintz, B.L. et al. (2012) MicroRNA targeting of neurotrophic Flavivirus: effective control of virus escape and reversion to neurovirulent phenotype. J. Virol. 86, 5647–5659
15. Saetrom, P. et al. (2007) Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res. 35, 2333–2342
16. Davis-Dusenbery, B.N. and Hata, A. (2010) Mechanisms of control of microRNA biogenesis. J. Biochem. 148, 381–392
17. Gaur, A. et al. (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 67, 2456–2466
18. Huwang, H.-W. et al. (2009) Cell–cell contact globally activates microRNA biogenesis. Proc. Natl. Acad. Sci. U.S.A. 106, 7016–7021
19. Lu, J. et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435, 834–838
20. Bradeney, D.E. et al. (2013) Dicerdeficient Aedes albopictus cells have a dysfunction of antiviral RNA interference response. PLoS Negl. Trop. Dis. 8, e2656
21. Scott, J.C. et al. (2010) Comparison of dengue virus type 2–specific small RNAs from RNA interference–competent and –incompetent mosquito cells. PLoS Negl. Trop. Dis. 4, e684
22. Bogerd, H.P. et al. (2014) Replication of many human viruses is refractory to inhibition by endogenous cellular microRNAs. J. Virol. 88, 8065–8076
23. Scheel, T.K.H. et al. (2016) A broad RNA virus survey reveals both miRNA dependence and functional sequestration. Cell Host Microbe 19, 429–433
24. Shimakami, T. et al. (2012) Stabilization of hepatitis C virus RNA by an Ago2–mir–122 complex. Proc. Natl. Acad. Sci. U.S.A. 109, 941–946
25. Laurant, A.S. et al. (2013) The role of mutational robustness in RNA virus evolution. Nat. Rev. Microbiol. 11, 327–336
26. Deresiewicz, R.L. et al. (1997) Clinical and neuroradiographic manifestations of eastern equine encephalitis. N. Engl. J. Med. 336, 1867–1874
27. Gardner, C.L. et al. (2008) Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis. J. Virol. 82, 10634–10646
28. Lecossier, C.-H. et al. (2005) A cellular microRNA mediates antiviral defense in human cells. Science 308, 557–560
29. Bai, X.T. and Nicot, C. (2015) mir-29-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection. J. Virol. Chem. 290, 5381–5390
30. Huang, J. et al. (2007) Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat. Med. 13, 1241–1247
31. Nathans, R. et al. (2009) Cellular microRNA and P bodies modulate host–HIV-1 interactions. Mol. Cell 34, 696–709
32. Wen, B.-P. et al. (2013) MicroRNA-21b inhibits enterovirus 71 replication through downregulation of EV71 VP protein. Intervirology 56, 195–200
33. Khongnomman, K. et al. (2015) Human miR-3145 inhibits influenza A viruses replication by targeting and silencing viral PB1 gene. Exp. Biol. Med. (Maywood) 240, 1630–1639
34. Inge, H. et al. (2015) The microRNA miR-485 targets host and influenza virus transcripts to regulate antiviral immunity and restrict viral replication. Sci. Signal. 8, ra126
35. Ma, Y.-J. et al. (2012) Cellular microRNA let-7c inhibits M1 protein expression of the H1N1 influenza A virus in infected human lung epithelial cells. J. Cell. Mol. Med. 16, 2539–2546
36. Zhang, H. et al. (2013) A computational method for predicting regulation of human microRNAs on the influenza virus genome. BMC Syst. Biol. 7, S3
37. He, T. et al. (2009) Identification of host encoded microRNAs interacting with novel swine-origin influenza A (H1N1) virus and swine influenza virus. Bioinformation 4, 112–118
38. Wang, Y.-S. et al. (2013) Overexpression of microRNA gga-miR-21 in chicken fibroblasts suppresses replication of infectious bursal disease virus through inhibiting VP1 translation. Antiviral Res. 100, 196–201
45. Guo, X-K. et al. (2013) Increasing expression of microRNA-181 inhibits virion replication and suppresses VSV-induced lung injury in a mouse model. J. Virol. 87, 1159–1171
40. Zhang, Q. et al. (2014) MicroRNA-23 inhibits PRPV RNA replication by targeting PROVirus RNA and possibly by upregulating type I interferons. Virology 450, 162–195
41. Weaver, S.C. et al. (1996) Genetic and fitness changes accompanying adaptation of an arterivirus to vertebrate and invertebrate cells. J. Virol. 73, 4316–4326
42. Pham, A.M. et al. (2012) Replication in cells of hematopoietic origin is necessary for dengue virus dissemination. PLoS Pathog. 8, e1002665
43. Janssen, H.L.A. et al. (2013) Treatment of HCV infection by targeting microRNA. Nat. Engl. J. Med. 368, 1685–1694
44. Wu, J. and Chen, Z.J. (2014) Inactive immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 32, 461–498
45. Aguado, L.C. et al. (2015) microRNA function is limited to cyto- kine control in the acute response to virus infection. Cell Host Microbe 18, 714–722
46. Choi, E-J. et al. (2014) Differential microRNA expression following infection with a mouse-adapted, highly virulent avian H5N2 virus. BMC Microbiol. 14, 184–193
47. Shin, D.S. et al. (2013) Hantaviruses induce cell type- and viral species-specific host microRNA expression signatures. Virology 448, 217–224
48. Luna, J.M. et al. (2015) Hepatitis C virus RNA functionality sequesters miR-122. Cell 160, 1099–1110
49. Beachboard, D.C. and Homer, S.M. (2016) Inactive immune eva- sion strategies of DNA and RNA viruses. Curr. Opin. Microbiol. 32, 113–119
50. Ho, B.C. et al. (2014) Inhibition of miR-146a prevents enterovirus- induced death by restoring the production of type I interferon. Nat. Commun. 5, 3344
51. Wu, S. et al. (2013) miR-146a facilitates replication of dengue virus by dampening interferon induction by targeting TRAF6. J. Infect. 67, 329–341
52. Sharma, N. et al. (2015) miR-146a suppresses cellular immune response during Japanese encephalitis virus Japa/AV/5890 strain infection in human microglial cells. J. Neuroinflammation 12, 30
53. Sharma, N. et al. (2016) Japanese encephalitis virus exploits the microRNA-432 to regulate the expression of suppressor of cytokine signaling (SOCS3). Sci. Rep. 6, 21685
54. Zhang, X. et al. (2014) Induction of the cellular miR-29c by influenza virus inhibits the innate immune response through protection of A20 mRNA. Biochem. Biophys. Res. Commun. 450, 755–761
55. Rosenberger, C.M. et al. (2012) miR-451 regulates dendritic cell cytokine responses to influenza infection. J. Immunol. 189, 5962–5975
56. Yang, Q. et al. (2014) Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758. Arch. Virol. 159, 2997–3003
57. Banjar Chowdhury, J. et al. (2012) Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-124a. J. Virol. 86, 10221–10225
58. Mukherjee, A. et al. (2015) Hepatitis C virus-mediated enhance- ment of microRNA miR-373 impairs the JAK/STAT signaling pathway. J. Virol. 89, 3356–3365
59. Li, Z. et al. (2015) MicroRNA-22b promotes avian leukosis virus subgroup (Alu-v) replication by targeting IFIP1. Sci. Rep. 5, 10294
60. Li, S. et al. (2014) MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J. Virol. Hepatol. 21, 121–128
61. Zhu, X. et al. (2014) MicroRNA-30c** suppresses dengue virus replication by promoting NF-kB-dependent IFN production. PLoS Negl. Trop. Dis. 8, e2608
62. Storchak, A. et al. (2016) Human microRNA miR-532-5p exhibits antiviral activity against West Nile virus via suppression of host genes SE17D7 and TAIM required for virus replication. J. Virol. 90, 2388–2402
63. Zhai, A. et al. (2013) Borna disease virus encoded phosphopro- tein inhibits host innate immunity by regulating miR-155. Antiviral Res. 96, 66–75
64. Lai, F.W. et al. (2014) Human coronavirus OC43 nucleocapsid protein binds microRNA 9 and potentiates NF-kB activation. J. Virol. 88, 54–65
65. Thromburg, N.J. et al. (2012) Respiratory syncytial virus regulates human microRNAs by using mechanisms involving beta interferon and NF-kB. MBio 3, e00220–e0112
66. Xu, C. et al. (2014) Downregulation of microRNA miR-526a by enterovirus inhibits RIG-I-dependent innate immune response. J. Virol. 88, 11356–11366
67. Balas, A. et al. (2012) Respiratory syncytial virus modifies micro- RNAs regulating host genes that affect virus replication. J. Gen. Virol. 93, 2346–2356
68. Loveday, E.K. et al. (2015) Human microRNA-24 modulates highly pathogenic avian-origin H5N1 influenza A virus infection in A549 cells by targeting secretory pathway factors. J. Gen. Virol. 96, 30–39
69. Oththumpangeth, S. et al. (2013) Expression of non-structural-1A binding protein in lung epithelial cells is modulated by miRNA-544a on exposure to influenza A virus. Virology 447, 84–94
70. Ho, B.C. et al. (2011) Enterovirus-induced miR-141 contributes to shutdown of host protein translation by targeting the translation initiation factor eIF4E. Cell Host Microbe 9, 58–69
71. Bandiera, S. et al. (2016) Hepatitis C virus-induced upregulation of microRNA miR-146b-5p in hepatocytes promotes viral infec- tion and deregulates metabolic pathways associated with liver disease pathogenesis. J. Virol. 90, 6387–6400
72. Oththumpangeth, S. et al. (2012) MicroRNA-221 modulates RSV replication in human bronchial epithelium by targeting NGF expression. PLoS One 7, e30030
73. Shim, B-S. et al. (2016) MicroRNA-555 has potent antiviral properties against poliovirus. J. Gen. Virol. 97, 659–669
74. Wolf, S. et al. (2016) MicroRNA regulation of human genes essential for influenza A (H7N9) replication. PLoS One 11, e0155104
75. Steinhauer, D.A. et al. (1990) Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 122, 281–288
76. Stalsky, R.L. et al. (2013) Identification of microRNAs expressed in two mosquito vectors, Aeolis albopictus and Culex quinque- fasciatus. BMC Genomics 11, 119
77. Kelly, E.J. and Russell, S.J. (2009) MicroRNAs and the regulation of vector tropism. Mol. Ther. 17, 409–416
78. Dunning, J. et al. (2016) Experimental treatment of Ebola virus disease with TKM-130803: a single-arm Phase 2 clinical trial. PLoS Med. 13, e1001997
79. Barnes, D. et al. (2008) Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4, 229–248
80. Hussain, M. and Aegasi, S. (2014) MicroRNA-like viral small RNA from dengue virus 2 autoregulates its replication in mosquito cells. Proc. Natl. Acad. Sci. U.S.A. 111, 2746–2751
81. Weng, K-F. et al. (2014) A cytoplasmic RNA virus generates functional viral small RNAs and regulates viral IRES activity in mammalian cells. Nucleic Acids Res. 42, 12769–12785
82. Ha, M. and Kim, V.N. (2014) Regulation of microRNA biogenesis. Nat. Immunol. 15, 509–524
83. Lee, Y. et al. (2003) The nuclear RNAse III Drosha initiates micro- RNA processing. Nature 425, 415–419
84. Eichhorn, S.W. et al. (2014) microRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repres- sion ensues. Mol. Cell 56, 104–115
85. Djuranovic, S. et al. (2012) microRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science 336, 237–240
86. Schwarz, D.S. et al. (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199–208
87. Amers, S.L. and Zamore, P.D. (2015) Diversifying microRNA sequence and function. Nat. Immunol. 14, 475–488
88. Lim, L.P. et al. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433, 769–773
89. Loeb, G.B. et al. (2012) Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting. Mol. Cell 48, 760–770
90. Agarwal, V. et al. (2015) Predicting effective microRNA target sites in mammalian mRNAs. J. Biol. 4, e00505.
91. Haasnoot, J. et al. (2007) The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog. 3, e86
92. Fabozzi, G. et al. (2011) Ebola virus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J. Virol. 85, 2512–2523
93. Wang, Y. et al. (2006) Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology 130, 883–892
94. Bennasser, Y. et al. (2005) Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 22, 607–619
95. Li W-X. et al. (2004) Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc. Natl. Acad. Sci. U. S. A. 101, 1350–1355
96. Langlois, P.A. et al. (2013) MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nat. Biotechnol. 31, 844–847
97. Sanghvi, V.R. and Steel, L.F. (2011) A re-examination of global suppression of RNA interference by HIV-1. PLoS One 6, e17246
98. Gammon, D.B. and Mello, C.C. (2015) RNA interference-mediated antiviral defense in insects. Curr. Opin. Insect Sci. 8, 111–120
99. Thounaojam, M.C. et al. (2014) MicroRNA-155 regulates Japanese encephalitis virus-induced inflammatory response by targeting Src homology 2-containing inositol phosphatase 1. J. Virol. 88, 4798–4810
100. Thounaojam, M.C. et al. (2014) MicroRNA-29b modulates Japanese encephalitis virus-induced microglia activation by targeting tumor necrosis factor alpha-induced protein 3. J. Neurochem. 129, 143–154
101. Zhu, B. et al. (2015) MicroRNA-15b modulates Japanese encephalitis virus-mediated inflammation via targeting RNF125. J. Immunol. 195, 2251–2262
102. Kumar, M. and Nerurkar, V.R. (2014) Integrated analysis of microRNAs and their disease related targets in the brain of mice infected with West Nile virus. Virology 452, 143–151
103. Wu, Z. et al. (2015) MicroRNA expression profile of mouse lung infected with 2009 pandemic H1N1 influenza virus. PLoS One 8, e71920
104. Buggele, W.A. et al. (2012) Influenza A virus infection of human respiratory cells induces primary microRNA expression. J. Biol. Chem. 287, 31027–31040
105. Lin, J. et al. (2016) MicroRNA-18b downregulates gap junction protein α1 and synergizes with microRNA-1 in viral myocarditis. Int. J. Mol. Sci. 17, 741
106. Xu, H-F. et al. (2011) MicroRNA-1 represses Cx43 expression in viral myocarditis. Mol. Cell. Biochem. 362, 141–148
107. Chang, Y-L. et al. (2015) miR-146a and miR-370 coordinate enterovirus 71-induced cell apoptosis through targeting SOS1 and GADD45β. Cell. Microbiol. 17, 802–818
108. Smith, J.L. et al. (2012) Induction of the cellular microRNA, Hs_154, by West Nile virus contributes to virus-mediated apoptosis through repression of antiapoptotic factors. J. Virol. 86, 5278–5287
109. Othumpanganat, S. et al. (2014) Lung epithelial cells resist influenza A infection by inducing the expression of cytochrome c oxidase V1c which is modulated by miRNA 4276. Virology 468, 256–264
110. Stewart, C.R. et al. (2013) Promotion of Hendra virus replication by microRNA 146a. J. Virol. 87, 3782–3791